820 related articles for article (PubMed ID: 29505844)
1. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
2. Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals.
Cuciureanu T; Stanciu C; Năstasă RR; Stratina LE; Minea HO; Zenovia IS; Sfarti C; Muzica CM; Huiban L; Stafie RT; Singeap AM; Chiriac Ş; Cojocariu EC; Gîrleanu I; Petrea OC; Timofeiov S; Cuciureanu ID; Rotaru A; Trifan A
Rom J Morphol Embryol; 2023; 64(4):483-491. PubMed ID: 38184828
[TBL] [Abstract][Full Text] [Related]
3. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection.
Ichikawa T; Miyaaki H; Miuma S; Motoyoshi Y; Narita S; Toda S; Takahashi Y; Honda T; Yajima H; Uehara R; Hino N; Hori T; Hirata R; Taura N; Nakao K
Intern Med; 2019 May; 58(9):1209-1215. PubMed ID: 30626818
[TBL] [Abstract][Full Text] [Related]
4. Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus.
Revuelto Artigas T; Betriu Bars À; Zaragoza Velasco N; Gómez Arbones X; Vidal Ballester T; Piñol Felis C; Reñé Espinet JM
Gastroenterol Hepatol; 2019; 42(6):362-371. PubMed ID: 30952463
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis.
Salomone F; Petta S; Micek A; Pipitone RM; Distefano A; Castruccio Castracani C; Rini F; Di Rosa M; Gardi C; Calvaruso V; Di Marco V; Li Volti G; Grimaudo S; Craxì A
Liver Int; 2020 Nov; 40(11):2820-2827. PubMed ID: 32666695
[TBL] [Abstract][Full Text] [Related]
6. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
Adinolfi LE; Rinaldi L; Nevola R
World J Gastroenterol; 2018 Nov; 24(41):4617-4621. PubMed ID: 30416309
[TBL] [Abstract][Full Text] [Related]
8. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
9. Effect of Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C.
Solis JG; Enciso López ES; Bautista Santos A; Anda Garay JC; Calixto Rodríguez JL; Moreno Alcántar R; Montiel López L
Arch Med Res; 2021 Oct; 52(7):764-771. PubMed ID: 33972118
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
11. Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study.
Novo G; Macaione F; Giannitrapani L; Minissale MG; Bonomo V; Indovina F; Petta S; Soresi M; Montalto G; Novo S; Craxi A; Licata A
Aliment Pharmacol Ther; 2018 Oct; 48(7):740-749. PubMed ID: 30095177
[TBL] [Abstract][Full Text] [Related]
12. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals.
Giannini EG; Crespi M; Demarzo M; Bodini G; Furnari M; Marabotto E; Torre F; Zentilin P; Savarino V
Eur J Clin Invest; 2019 Mar; 49(3):e13056. PubMed ID: 30474209
[TBL] [Abstract][Full Text] [Related]
13. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
[TBL] [Abstract][Full Text] [Related]
14. Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients.
Cheng PN; Chen JY; Chiu YC; Chiu HC; Tsai LM
Sci Rep; 2019 Feb; 9(1):1426. PubMed ID: 30723238
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
[TBL] [Abstract][Full Text] [Related]
17. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
19. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review.
Cespiati A; Coelho Rodrigues I; Santos I; Policarpo S; Carvalhana S; Fracanzani AL; Cortez-Pinto H
Liver Int; 2024 May; 44(5):1075-1092. PubMed ID: 38385567
[TBL] [Abstract][Full Text] [Related]
20. Reversion of disease manifestations after HCV eradication.
van der Meer AJ; Berenguer M
J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
